Inhibiting the expression of CD28 costimulatory molecule on human lymphocytes by special siRNA

Kai-lin Xu1, Ying Zhang, Xiu-ying Pan

  • 1Department of Hematology, Affiliated Hospital of Xuzhou Medical College, Xuzhou 221002, China. xukailin@hotmail.com

Abstract

Insights

Small interfering RNA (siRNA) targeting CD28 mRNA effectively reduces CD28 expression and mRNA levels in human lymphocytes. siRNA-2 demonstrated the highest efficiency, leading to reduced cell viability and potential applications in costimulatory blockade for graft-versus-host disease.

Area of Science:

  • Immunology
  • Molecular Biology
  • RNA Interference

Background:

  • The B7/CD28 pathway is crucial for T cell activation and a target for immunotherapy.
  • Investigating RNA interference (RNAi) induced by small interfering RNA (siRNA) targeting CD28 mRNA in human lymphocytes.

Purpose of the Study:

  • To evaluate the RNA interference (RNAi) effect and specificity of siRNAs targeting CD28 mRNA in human lymphocytes.
  • To assess the impact of CD28 mRNA silencing on T cell activation and viability.

Main Methods:

  • Design and synthesis of three distinct 21-base siRNAs targeting CD28 mRNA.
  • Transfection of siRNAs into human lymphocytes using Lipofectamine 2000.
  • Analysis of CD28 surface expression (flow cytometry) and mRNA levels (RT-PCR) at 24, 48, and 72 hours post-transfection.
  • Assessment of cell viability using MTT assay and trypan blue dye exclusion assay.

Main Results:

  • Successfully designed and constructed three siRNAs targeting CD28 mRNA.
  • Significant reduction in CD28 expression observed starting at 24 hours post-transfection, with siRNA-2 showing the highest inhibition (73.50% +/- 1.02%) at 48 hours.
  • RT-PCR confirmed CD28 mRNA level inhibition, with siRNA-2 causing at least a 4-fold reduction.
  • Transfection with siRNAs led to a significant reduction in viable lymphocyte counts.

Conclusions:

  • Synthesized siRNAs effectively reduced CD28 expression and mRNA levels in lymphocytes, with siRNA-2 being the most potent.
  • The observed reduction in CD28 expression and cell viability suggests siRNA-induced silencing may contribute to costimulatory blockade.
  • These findings indicate siRNA's potential utility in further research on graft-versus-host disease (GVHD) following allogeneic bone marrow transplantation (allo-BMT).